CCL18 as a immunosuppressive biomarker for prognosis in ABC diffuse large B-cell Lymphoma

ABSTRACT: Objective: decipher TME of ABC lymphomas to describe new biomarkers and treatment strategies. Methods: We analyzed 43 DLBCL samples (23 GCB and 20 ABC) by Nanosring PanCancer Immune Profiling Panel with additional 30 cell-of-origin genes. ABC lymphomas showed distinct expression profile than GCB with a markedly downregulation of MAPK10, more entropy with eosinophils enrichment. Multivariate analysis identified CCL18 as an independent adverse prognostic factor in ABC. lymphomas. Connectivity mapping identified proteasome inhibitors and CDK4/6 inhibitors as promising therapeutic candidates.

ORGANISM(S): Homo sapiens

PROVIDER: GSE306513 | GEO | 2026/01/12

REPOSITORIES: GEO